μ Opioid receptor phosphorylation, desensitization, and ligand efficacy

Yunkai Yu, Li Zhang, Xixi Yin, Hui Sun, George R. Uhl, Jia Bei Wang

Research output: Contribution to journalArticle

Abstract

μ opioid receptors are subject to phosphorylation and desensitization through actions of at least two distinct biochemical pathways: agonist- dependent μ receptor phosphorylation and desensitization induced by a biochemically distinct second pathway dependent on protein kinase C activation (1). To better understand the nature of the agonist-induced μ receptor phosphorylation events, we have investigated the effects of a variety of opiate ligands of varying potencies and intrinsic activities on μ receptor phosphorylation and desensitization. Exposure to the potent full agonists sufentanil, dihydroetorphine, etorphine, etonitazine, and [D-Ala2, MePhe4, Glyo15]enkephalin (DAMGO) led to strong receptor phosphorylation, while methadone, l-α-acetyl-methadone (LAAM), morphine, meperidine, DADL, β-endorphin((1-31)), enkephalins, and dynorphin A((1-17)) produced intermediate effects. The partial agonist buprenorphine minimally enhanced receptor phosphorylation while antagonists failed to alter phosphorylation. Buprenorphine and full antagonists each antagonized the enhanced μ receptor phosphorylation induced by morphine or DAMGO. The rank order of opiate ligand efficacies in producing μ receptor-mediated functional desensitization generally paralleled their rank order of efficacies in producing receptor phosphorylation. Interestingly, the desensitization and phosphorylation mediated by methadone and LAAM were disproportionate to their efficacies in two distinct test systems. This generally good fit between the efficacies of opiates in μ receptor activation, phosphorylation, and desensitzation supports the idea that activated receptor/agonist/G-protein complexes and/or receptor conformational changes induced by agonists are required for agonist- induced μ receptor phosphorylation. Data for methadone and LAAM suggest possible contribution from their enhanced desensitizing abilities to their therapeutic efficacies.

Original languageEnglish (US)
Pages (from-to)28869-28874
Number of pages6
JournalJournal of Biological Chemistry
Volume272
Issue number46
DOIs
StatePublished - Nov 14 1997

Fingerprint

Phosphorylation
Opioid Receptors
Ligands
Opiate Alkaloids
Methadyl Acetate
Methadone
Enkephalins
Buprenorphine
Morphine
Chemical activation
Etorphine
Sufentanil
Endorphins
Dynorphins
Meperidine
GTP-Binding Proteins
Protein Kinase C

ASJC Scopus subject areas

  • Biochemistry

Cite this

Yu, Y., Zhang, L., Yin, X., Sun, H., Uhl, G. R., & Wang, J. B. (1997). μ Opioid receptor phosphorylation, desensitization, and ligand efficacy. Journal of Biological Chemistry, 272(46), 28869-28874. https://doi.org/10.1074/jbc.272.46.28869

μ Opioid receptor phosphorylation, desensitization, and ligand efficacy. / Yu, Yunkai; Zhang, Li; Yin, Xixi; Sun, Hui; Uhl, George R.; Wang, Jia Bei.

In: Journal of Biological Chemistry, Vol. 272, No. 46, 14.11.1997, p. 28869-28874.

Research output: Contribution to journalArticle

Yu, Y, Zhang, L, Yin, X, Sun, H, Uhl, GR & Wang, JB 1997, 'μ Opioid receptor phosphorylation, desensitization, and ligand efficacy', Journal of Biological Chemistry, vol. 272, no. 46, pp. 28869-28874. https://doi.org/10.1074/jbc.272.46.28869
Yu, Yunkai ; Zhang, Li ; Yin, Xixi ; Sun, Hui ; Uhl, George R. ; Wang, Jia Bei. / μ Opioid receptor phosphorylation, desensitization, and ligand efficacy. In: Journal of Biological Chemistry. 1997 ; Vol. 272, No. 46. pp. 28869-28874.
@article{510b57a51cde49cb93c2bae078fe9165,
title = "μ Opioid receptor phosphorylation, desensitization, and ligand efficacy",
abstract = "μ opioid receptors are subject to phosphorylation and desensitization through actions of at least two distinct biochemical pathways: agonist- dependent μ receptor phosphorylation and desensitization induced by a biochemically distinct second pathway dependent on protein kinase C activation (1). To better understand the nature of the agonist-induced μ receptor phosphorylation events, we have investigated the effects of a variety of opiate ligands of varying potencies and intrinsic activities on μ receptor phosphorylation and desensitization. Exposure to the potent full agonists sufentanil, dihydroetorphine, etorphine, etonitazine, and [D-Ala2, MePhe4, Glyo15]enkephalin (DAMGO) led to strong receptor phosphorylation, while methadone, l-α-acetyl-methadone (LAAM), morphine, meperidine, DADL, β-endorphin((1-31)), enkephalins, and dynorphin A((1-17)) produced intermediate effects. The partial agonist buprenorphine minimally enhanced receptor phosphorylation while antagonists failed to alter phosphorylation. Buprenorphine and full antagonists each antagonized the enhanced μ receptor phosphorylation induced by morphine or DAMGO. The rank order of opiate ligand efficacies in producing μ receptor-mediated functional desensitization generally paralleled their rank order of efficacies in producing receptor phosphorylation. Interestingly, the desensitization and phosphorylation mediated by methadone and LAAM were disproportionate to their efficacies in two distinct test systems. This generally good fit between the efficacies of opiates in μ receptor activation, phosphorylation, and desensitzation supports the idea that activated receptor/agonist/G-protein complexes and/or receptor conformational changes induced by agonists are required for agonist- induced μ receptor phosphorylation. Data for methadone and LAAM suggest possible contribution from their enhanced desensitizing abilities to their therapeutic efficacies.",
author = "Yunkai Yu and Li Zhang and Xixi Yin and Hui Sun and Uhl, {George R.} and Wang, {Jia Bei}",
year = "1997",
month = "11",
day = "14",
doi = "10.1074/jbc.272.46.28869",
language = "English (US)",
volume = "272",
pages = "28869--28874",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "46",

}

TY - JOUR

T1 - μ Opioid receptor phosphorylation, desensitization, and ligand efficacy

AU - Yu, Yunkai

AU - Zhang, Li

AU - Yin, Xixi

AU - Sun, Hui

AU - Uhl, George R.

AU - Wang, Jia Bei

PY - 1997/11/14

Y1 - 1997/11/14

N2 - μ opioid receptors are subject to phosphorylation and desensitization through actions of at least two distinct biochemical pathways: agonist- dependent μ receptor phosphorylation and desensitization induced by a biochemically distinct second pathway dependent on protein kinase C activation (1). To better understand the nature of the agonist-induced μ receptor phosphorylation events, we have investigated the effects of a variety of opiate ligands of varying potencies and intrinsic activities on μ receptor phosphorylation and desensitization. Exposure to the potent full agonists sufentanil, dihydroetorphine, etorphine, etonitazine, and [D-Ala2, MePhe4, Glyo15]enkephalin (DAMGO) led to strong receptor phosphorylation, while methadone, l-α-acetyl-methadone (LAAM), morphine, meperidine, DADL, β-endorphin((1-31)), enkephalins, and dynorphin A((1-17)) produced intermediate effects. The partial agonist buprenorphine minimally enhanced receptor phosphorylation while antagonists failed to alter phosphorylation. Buprenorphine and full antagonists each antagonized the enhanced μ receptor phosphorylation induced by morphine or DAMGO. The rank order of opiate ligand efficacies in producing μ receptor-mediated functional desensitization generally paralleled their rank order of efficacies in producing receptor phosphorylation. Interestingly, the desensitization and phosphorylation mediated by methadone and LAAM were disproportionate to their efficacies in two distinct test systems. This generally good fit between the efficacies of opiates in μ receptor activation, phosphorylation, and desensitzation supports the idea that activated receptor/agonist/G-protein complexes and/or receptor conformational changes induced by agonists are required for agonist- induced μ receptor phosphorylation. Data for methadone and LAAM suggest possible contribution from their enhanced desensitizing abilities to their therapeutic efficacies.

AB - μ opioid receptors are subject to phosphorylation and desensitization through actions of at least two distinct biochemical pathways: agonist- dependent μ receptor phosphorylation and desensitization induced by a biochemically distinct second pathway dependent on protein kinase C activation (1). To better understand the nature of the agonist-induced μ receptor phosphorylation events, we have investigated the effects of a variety of opiate ligands of varying potencies and intrinsic activities on μ receptor phosphorylation and desensitization. Exposure to the potent full agonists sufentanil, dihydroetorphine, etorphine, etonitazine, and [D-Ala2, MePhe4, Glyo15]enkephalin (DAMGO) led to strong receptor phosphorylation, while methadone, l-α-acetyl-methadone (LAAM), morphine, meperidine, DADL, β-endorphin((1-31)), enkephalins, and dynorphin A((1-17)) produced intermediate effects. The partial agonist buprenorphine minimally enhanced receptor phosphorylation while antagonists failed to alter phosphorylation. Buprenorphine and full antagonists each antagonized the enhanced μ receptor phosphorylation induced by morphine or DAMGO. The rank order of opiate ligand efficacies in producing μ receptor-mediated functional desensitization generally paralleled their rank order of efficacies in producing receptor phosphorylation. Interestingly, the desensitization and phosphorylation mediated by methadone and LAAM were disproportionate to their efficacies in two distinct test systems. This generally good fit between the efficacies of opiates in μ receptor activation, phosphorylation, and desensitzation supports the idea that activated receptor/agonist/G-protein complexes and/or receptor conformational changes induced by agonists are required for agonist- induced μ receptor phosphorylation. Data for methadone and LAAM suggest possible contribution from their enhanced desensitizing abilities to their therapeutic efficacies.

UR - http://www.scopus.com/inward/record.url?scp=0030691760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030691760&partnerID=8YFLogxK

U2 - 10.1074/jbc.272.46.28869

DO - 10.1074/jbc.272.46.28869

M3 - Article

C2 - 9360954

AN - SCOPUS:0030691760

VL - 272

SP - 28869

EP - 28874

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 46

ER -